PharmacyCodes



Ethyl p-chlorophenoxyisobutyrate en es it fr

Ethyl p-chlorophenoxyisobutyrate Brand names, Ethyl p-chlorophenoxyisobutyrate Analogs

Ethyl p-chlorophenoxyisobutyrate Brand Names Mixture

  • No information avaliable

Ethyl p-chlorophenoxyisobutyrate Chemical_Formula

C12H15ClO3

Ethyl p-chlorophenoxyisobutyrate RX_link

http://www.rxlist.com/cgi/generic2/clofibrate.htm

Ethyl p-chlorophenoxyisobutyrate fda sheet

Ethyl p-chlorophenoxyisobutyrate msds (material safety sheet)

Ethyl_p-chlorophenoxyisobutyrate MSDS

Ethyl p-chlorophenoxyisobutyrate Synthesis Reference

No information avaliable

Ethyl p-chlorophenoxyisobutyrate Molecular Weight

242.698 g/mol

Ethyl p-chlorophenoxyisobutyrate Melting Point

< 25 oC (boiling point 148-150°C at 25 mm Hg)

Ethyl p-chlorophenoxyisobutyrate H2O Solubility

Insoluble

Ethyl p-chlorophenoxyisobutyrate State

Liquid

Ethyl p-chlorophenoxyisobutyrate LogP

3.58

Ethyl p-chlorophenoxyisobutyrate Dosage Forms

Capsules (orange, oblong, soft-gelatin capsules, each containing 500 mg clofibrate)

Ethyl p-chlorophenoxyisobutyrate Indication

For Primary Dysbetalipoproteinemia (Type III hyperlipidemia) that does not respond adequately to diet.

Ethyl p-chlorophenoxyisobutyrate Pharmacology

Clofibrate is an antilipidemic agent similar to gemfibrozil. It acts to lower elevated serum lipids by reducing the very low-density lipoprotein fraction (Sf 20-400) rich in triglycerides. Serum cholesterol may be decreased, particularly in those patients whose cholesterol elevation is due to the presence of IDL as a result of Type III hyperlipoproteinemia. Several investigators have observed in their studies that clofibrate may produce a decrease in cholesterol linoleate but an increase in palmitoleate and oleate, the latter being considered atherogenic in experimental animals. The significance of this finding is unknown at this time. Reduction of triglycerides in some patients treated with clofibrate or certain of its chemically and clinically similar analogs may be associated with an increase in LDL cholesterol. Increase in LDL cholesterol has been observed in patients whose cholesterol is initially normal. Animal studies suggest that clofibrate interrupts cholesterol biosynthesis prior to mevalonate formation.

Ethyl p-chlorophenoxyisobutyrate Absorption

Completely but slowly absorbed from the intestine. Between 95% and 99% of an oral dose of clofibrate is excreted in the urine as free and conjugated clofibric acid; thus, the absorption of clofibrate is virtually complete.

Ethyl p-chlorophenoxyisobutyrate side effects and Toxicity

Oral, mouse: LD50 = 1220 mg/kg; Oral, rabbit: LD50 = 1370 mg/kg; Oral, rat: LD50 = 940 mg/kg. No reported case of overdosage in humans.

Ethyl p-chlorophenoxyisobutyrate Patient Information

Ethyl p-chlorophenoxyisobutyrate Organisms Affected

Humans and other mammals